GLPwatch
Antiproteinuric Effects of Liraglutide Treatment
NCT02545738 · Completed
Last updated 2026-05-28This clinical trial tested whether the medication liraglutide reduces protein in the urine of people with diabetic kidney disease.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 32 people
Who can join Ages 18+ · all sexes
Timeline Started 2015-04 · est. completion 2016-05
Where 1 site · Denmark
What this study is testing ClinicalTrials.gov NCT02545738 ↗
Description as written by the study sponsor.
The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.
Treatments tested
- Liraglutide also known as Victoza Drug
active treatment
- placebo Drug
placebo
| Main thing measured | Change in albuminuria |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Conditions studied | Diabetic Kidney Disease |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02545738 ↗